Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: A new noninvasive predictive assay

Mayr, Nina A.; Yuh, William T. C.; Magnotta, Vincent A.; Ehrhardt, James C.; Wheeler, James; Sorosky, Joel I.; Davis, Charles S.; Wen, B‐Chen; Martin, Douglas D.; Pelsang, Retta E.; Buller, Richard E.; Oberley, Larry W.; Mellenberg, David E.; Hussey, David H.

doi:10.1016/s0360-3016(97)85090-0

Cited by 196 publications

(135 citation statements)

References 30 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…[9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24] Pharmacokinetically deˆned permeability provides a high sensitivity in classifying benign and malignant breast lesions. 10 Most head and neck tumors and uterine cervical tumors are squamous cell carcinomas, and radiation therapy is useful in the treatment of these tumors.…”

Section: Introductionmentioning

confidence: 99%

Dynamic MR Imaging and Radiotherapy

2002

View full text Add to dashboard Cite

Dynamic MRI has been used to improve the detection of tumors and to make diŠerential diagnosis. Most malignant lesions show early enhancement and early washout of contrast media on dynamic MRI, but the characterization of the tumor remains unclear. Pharmacokinetic analysis of dynamic MRI can provide information about the permeability of contrast media in the tumor that may re‰ect the oxygen concentration of the tumor. This information may be useful in the prediction of a tumor's response to radiation therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Dynamic MR Imaging and Radiotherapy

2002

View full text Add to dashboard Cite

show abstract

“…According to their results, MR imaging has been proved to be an independent predictive factor in osteosarcoma after pre-operative chemotherapy. A study of MAYR et al (12) showed that MR perfusion examinations might offer important information on treatment outcome in advanced cervical cancer. HAWIGHORST et al (9) assessed the angiogenic activity of cervical cancer by conventional morphologic methods, and compared them with pharmacokinetic MR imaging.…”

Section: Discussionmentioning

confidence: 99%

Can contrast-enhanced MR imaging predict survival in breast cancer?

Boné

Szabó

Perbeck³

et al. 2003

Acta Radiol

View full text Add to dashboard Cite

Purpose: To investigate the value of pre-operative contrast-enhanced MR imaging (CE-MRI) in predicting the disease-free and overall survival in breast cancer.Material and Methods: The study population consisted of 50 consecutive patients with histopathologically verified primary breast cancer who preoperatively underwent CE-MRI examination between 1992 and 1993. A threetime point MR examination was performed where the enhancement rates (C 1 and C 2 ), signal enhancement ratio (SER ¼ C 1 /C 2 ) and washout (W ¼ C 1 -C 2 ) were calculated. The relation of these MR parameters to disease-free and overall survival was investigated. The median follow-up for surviving patients was 95 months. Univariate and multivariate statistical analyses were performed to evaluate the impact of different factors on prediction of survival.Results: Of the MR parameters examined at univariate analysis, increased C 1 (p ¼ 0.029), W (p ¼ 0.0081) and SER values (p ¼ 0.0081) were significantly associated with shorter disease-free survival, and only C 1 (p ¼ 0.016) was related significantly to overall survival. Multivariate analysis for disease-free survival showed that the SER (p ¼ 0.014) and tumor size (p ¼ 0.001) were significant and independent predictors. Age (p ¼ 0.003), lymph node status (p ¼ 0.014), tumor size (p ¼ 0.039) and proliferating cell nuclear antigen index (p ¼ 0.053) remained independently associated with overall survival at multivariate analysis. C 1 was not confirmed as an independent predictor of overall survival.Conclusion: Our findings support the presumption that CE-MRI is useful in predicting the disease-free survival in patients with breast cancer.The conventional TNM classification system for staging of breast cancer is widely used to determine treatment and provides prognostic information (1). The pre-operative staging is based on a combination of clinical and imaging findings and includes the assessment of tumor extent, multifocality and lymph node status. Mammography and breast ultrasonography, however, often underestimate the extent of the disease. MR imaging has been introduced as a complementary diagnostic tool for the detection of breast cancer. It is widely accepted that MR imaging can reveal mammographically occult breast malignancy, and has the ability to determine tumor size and exclude multifocality more accurately than standard breast imaging methods (2). Recently, MR imaging has also been suggested for pre-operative loco-regional staging, as well as for the evaluation of response to preoperative chemotherapy (8,14).Although staging is very important in the clinical management and contains information on tumor size and nodal involvement, treatment planning and prediction of prognosis cannot be made without the assessment of other postoperative morphologic variables such as histologic type and malignancy grade. Besides these classic prognostic factors, a number of biological markers have also

show abstract

“…In fact, pre- treatment and midtherapy magnetic resonance perfusion imaging of cervical carcinoma demonstrates a good therapeutic effect on patients with increased tumor perfusion. 30 However, hyperthermia causes damage to blood vessels, and acute hypoxia resulting from the temporary closing of tumor blood vessel is decreased. Chronic hypoxic and necrotic areas in the tumor may be increased relative to prehyperthermia, and midtherapy CT studies showed a statistically significant reduction in ⌬CT max in CR patients.…”

Section: Discussionmentioning

confidence: 99%